LX 101
Alternative Names: LX-101Latest Information Update: 09 Apr 2024
At a glance
- Originator Lirum Therapeutics
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies
- Mechanism of Action IGF type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
- Preclinical Autoimmune disorders; Graves ophthalmopathy
Most Recent Events
- 09 Apr 2024 Preclinical trials in Autoimmune disorders in USA
- 05 Apr 2024 Updated pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 26 Feb 2024 Efficacy data from a phase Ia trial in Cancer released by Lirum Therapeutics